{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:20:34Z","timestamp":1740136834761,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We conducted a real-life study of health-related quality of life (HRQoL) transformation before and 12\u00a0weeks after sofosbuvir and daclatasvir therapy in HCV\/HIV co-infected patients. Factors related to the significant changes of each HRQoL domain\/item were also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A prospective study was performed in the HIV integrated clinic at Cipto Mangunkusumo Hospital, Jakarta. HCV\/HIV co-infected patients who started sofosbuvir and daclatasvir from government free DAA program in 2017\u20132019. WHOQoL-HIV BREF and RAND SF-36 questionnaires were recorded at baseline and post-treatment week 12.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>145 patients with mean age of 37.8\u00a0years (SD\u2009=\u20094.2) were included in the analysis. Most of patients were male (89%), previous IVDU (89%), active smoker (50.4%) and non-cirrhosis (80%). SVR12 was achieved in 95.5% of patients. Sofosbuvir and daclatasvir treatments showed positive impacts on 2 domains and 2 other items of WHOQoL-HIV BREF and 2 domains and 1 item of SF-36. Predicting factors of significant increase in each domain\/item were: male and normal body mass index (BMI) for level of independence (RR 4.01,95% CI 1.09\u201314.74 and 4.80,95% CI 1.79\u201312.81); higher HCV-RNA for overall perception of QoL (RR 0.42,95% CI 0.18\u20130.94); non-smoking status for overall perception of health (RR 0.32,95% CI 0.15\u20130.66); male and fibrosis stage 0\u20131 for general health (RR 6.21,95% CI 1.69\u201322.88 and 2.86,95% CI 1.16\u20137.00); and the use of NNRTI-based ART (RR 5.23, 95% CI 1.16\u201323.65). Spiritual\/personal belief decline was predicted by non-smoking status (RR 0.46, 95% CI 0.23\u20130.95). Treatment success was not associated with any changes of HR-QoL domain\/item.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>HCV\/HIV co-infected patients were successfully treated with sofosbuvir and daclatasvir and experienced improvement of HRQoL 12\u00a0weeks after treatment completion.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12955-021-01777-x","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T10:02:58Z","timestamp":1622023378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-0559","authenticated-orcid":false,"given":"Evy","family":"Yunihastuti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fhadilla","family":"Amelia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arini Ika","family":"Hapsari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bramantya","family":"Wicaksana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veritea","family":"Natali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvina","family":"Widhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andri Sanityoso","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teguh Harjono","family":"Karjadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1777_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt L, Easterbrook P, Gower E, Al E. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797\u2013808.","journal-title":"Lancet Infect Dis"},{"key":"1777_CR2","doi-asserted-by":"crossref","unstructured":"Hernandez, MD. Sherman K. HIV\/HCV coinfection natural history and disease progression, a review of the most recent literature. Curr Opin HIV AIDS 2011; 6: 478\u201382.","DOI":"10.1097\/COH.0b013e32834bd365"},{"key":"1777_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","volume":"384","author":"CJ Smith","year":"2014","unstructured":"Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241\u20138.","journal-title":"Lancet"},{"key":"1777_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2468-2667(16)30020-2","volume":"2","author":"S Croxford","year":"2017","unstructured":"Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet public Heal. 2017;2:35\u201346.","journal-title":"Lancet public Heal"},{"key":"1777_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2012.06.010","volume":"57","author":"V Hernando","year":"2012","unstructured":"Hernando V, Perez-Cachafeiro S, Lewden C, Gonzalez J, Segura F, Oteo JA, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol. 2012;57:743\u201351.","journal-title":"J Hepatol"},{"key":"1777_CR6","first-page":"69","volume":"18","author":"M Martinello","year":"2016","unstructured":"Martinello M, Amin J, Matthews GV, Dore GJ. Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: a systematic review and meta-analysis. AIDS Rev. 2016;18:69\u201380.","journal-title":"AIDS Rev"},{"key":"1777_CR7","unstructured":"World Health Organization. Hepatitis C. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"1777_CR8","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMp1400986","volume":"370","author":"RT Chung","year":"2014","unstructured":"Chung RT, Baumert TF. Curing chronic hepatitis C\u2014the arc of a medical triumph. N Engl J Med. 2014;370:1576\u20138.","journal-title":"N Engl J Med"},{"key":"1777_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12072-018-9896-4","volume":"12","author":"A Abutaleb","year":"2018","unstructured":"Abutaleb A, Sherman KE. A changing paradigm: management and treatment of the HCV\/HIV-co-infected patient. Hepatol Int. 2018;12:500\u20139.","journal-title":"Hepatol Int"},{"key":"1777_CR10","volume-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneve: WHO; 2018."},{"key":"1777_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.31887\/DCNS.2014.16.2\/mbullinger","volume":"16","author":"M Bullinger","year":"2014","unstructured":"Bullinger M, Quitmann J. Quality of life as patient-reported outcomes: principles of assessment. Dialogues Clin Neurosci. 2014;16:137\u201345.","journal-title":"Dialogues Clin Neurosci"},{"key":"1777_CR12","unstructured":"World Health Organization. WHOQOL: measuring quality of life. https:\/\/www.who.int\/healthinfo\/survey\/whoqol-qualityoflife\/en\/."},{"key":"1777_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/jvh.12554","volume":"23","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Henry L, Hunt S. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016;23:857\u201365.","journal-title":"J Viral Hepat"},{"key":"1777_CR14","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.2196\/cancer.7443","volume":"3","author":"WG Groen","year":"2017","unstructured":"Groen WG, Kuijpers W, Oldenburg HS, Wouters MW, Aaronson NK, van Harten WH. Supporting lung cancer patients with an interactive patient portal: feasibility study. JMIR Cancer. 2017;3:e10.","journal-title":"JMIR Cancer"},{"key":"1777_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4103\/0975-1483.93568","volume":"4","author":"P Muragundi","year":"2012","unstructured":"Muragundi P, Tumkur A, Shetty R, Naik A. Health-related quality of life measurement. J Young Pharm. 2012;4:54.","journal-title":"J Young Pharm"},{"key":"1777_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/apt.13090","volume":"41","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C\u2014the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497\u2013520.","journal-title":"Aliment Pharmacol Ther"},{"key":"1777_CR17","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/hep.27161","volume":"59","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014;59:2161\u20139.","journal-title":"Hepatology"},{"key":"1777_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/apt.12880","volume":"40","author":"M Stepanova","year":"2014","unstructured":"Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi Z. Patients\u2019 preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014;40:676\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"1777_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jhep.2016.02.042","volume":"65","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Feld J, Zeuzem J, Jacobson I, Agarwal K, et al. Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65:33\u20139.","journal-title":"J Hepatol"},{"key":"1777_CR20","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/cid\/ciw496","volume":"63","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with geno- types 2 and 3 chronic hepatitis C: results from Astral-2 and -3 clinical trials. Clin Infect Dis. 2016;63:1042\u20138.","journal-title":"Clin Infect Dis"},{"key":"1777_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10865-016-9778-y","volume":"39","author":"M Pereira","year":"2016","unstructured":"Pereira M, Fialho R. Assessment of factors associated with the quality of life of patients living with HIV\/HCV co-infection. J Behav Med. 2016;39:767\u201381.","journal-title":"J Behav Med"},{"key":"1777_CR22","first-page":"445","volume":"111","author":"S Go\u00f1i-Esarte","year":"2019","unstructured":"Go\u00f1i-Esarte S, Juanbeltz R, Mart\u00ednez-Baz I, Castilla J, Miguel RS, Herrero JI, et al. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enfermedades Dig. 2019;111:445\u201352.","journal-title":"Rev Esp Enfermedades Dig"},{"key":"1777_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000004061","volume":"95","author":"B Scheiner","year":"2016","unstructured":"Scheiner B, Schwabl P, Steiner S, Bucsics T, Chromy D, Aichelburg MC, et al. Interferon-free regimens improve health-related quality of life and fatigue in HIV\/HCV-coinfected patients with advanced liver disease. Medicine. 2016;95:1\u20138.","journal-title":"Medicine"},{"key":"1777_CR24","unstructured":"World Health Organization. Progress report on access to hepatitis C treatment. Focus on overcoming access barriers: experiences of selected countries. 2018. https:\/\/www.who.int\/hepatitis\/publications\/hep-c-access-report-2018\/en\/."},{"key":"1777_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3851\/IMP2674","volume":"18","author":"M Bifano","year":"2013","unstructured":"Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18:931\u201340.","journal-title":"Antivir Ther"},{"key":"1777_CR26","first-page":"1","volume":"11","author":"TN Truong","year":"2016","unstructured":"Truong TN, Laureillard D, Lacombe K, Thi HD, Hanh PPT, Xuan LTT, et al. High proportion of HIV-HCV coinfected patients with advanced liver fibrosis requiring hepatitis C treatment in Haiphong, Northern Vietnam. PLoS ONE. 2016;11:1\u201313.","journal-title":"PLoS ONE"},{"key":"1777_CR27","unstructured":"World Health Organization. WHOQOL-HIV Instrument Users Manual. 2002."},{"key":"1777_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","volume":"51","author":"JE Ware","year":"1998","unstructured":"Ware JE, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol. 1998;51:903\u201312.","journal-title":"J Clin Epidemiol"},{"key":"1777_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7454\/jpdi.v4i3.137","volume":"4","author":"NN Muhammad","year":"2017","unstructured":"Muhammad NN, Shatri H, Djoerban Z, Abdullah M. Uji kesahihan dan keandalan kuesioner World Health Organization Quality of Life-HIV Bref dalam bahasa indonesia untuk mengukur kualitas hidup pasien HIV\/AIDS. J Penyakit Dalam Indones. 2017;4:112.","journal-title":"J Penyakit Dalam Indones"},{"key":"1777_CR30","first-page":"10","volume":"49","author":"S Salim","year":"2017","unstructured":"Salim S, Yamin M, Alwi I, Setiati S. Validity and reliability of the Indonesian version of SF-36 quality of life questionnaire on patients with permanent pacemakers. Acta Medica Indones. 2017;49:10\u20136.","journal-title":"Acta Medica Indones"},{"key":"1777_CR31","first-page":"2","volume":"39","author":"NW Astoro","year":"2007","unstructured":"Astoro NW, Djauzi S, Djoerban Z, Prodjosudjadi W. Quality of life of HIV patients and influential factors. Acta Med Indones. 2007;39:2\u20137.","journal-title":"Acta Med Indones"},{"key":"1777_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/hep.510290124","volume":"29","author":"HLWJ Bonkovsky","year":"1999","unstructured":"Bonkovsky HLWJ. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999;29:264\u201370.","journal-title":"Hepatology"},{"key":"1777_CR33","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa040842","volume":"351","author":"FJ Torriani","year":"2004","unstructured":"Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV- infected patients. N Engl J Med. 2004;351:438\u201350.","journal-title":"N Engl J Med"},{"key":"1777_CR34","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/liv.13462","volume":"37","author":"ZM Younossi","year":"2017","unstructured":"Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study. Liver Int. 2017;37:1796\u2013804.","journal-title":"Liver Int"},{"key":"1777_CR35","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/cid\/civ1222","volume":"62","author":"S Saeed","year":"2016","unstructured":"Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferri\u00e8re V, et al. How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV\/HCV in the real world? Clin Infect Dis. 2016;62:919\u201326.","journal-title":"Clin Infect Dis"},{"key":"1777_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1179\/501100000024","volume":"16","author":"MW Yeung","year":"2015","unstructured":"Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, et al. Changes in quality of life, healthcare use, and substance use in HIV\/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clin Trials. 2015;16:100\u201310.","journal-title":"HIV Clin Trials"},{"key":"1777_CR37","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jvh.12985","volume":"25","author":"S Saeed","year":"2018","unstructured":"Saeed S, Moodie EEM, Strumpf E, Gill J, Wong A, Cooper C, et al. Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV\/Hepatitis C co-infected individuals. J Viral Hepat. 2018;25:1507\u201314.","journal-title":"J Viral Hepat"},{"key":"1777_CR38","doi-asserted-by":"crossref","unstructured":"Bakiono F, Ou\u00e9draogo L, Sanou M, Samadoulougou S, Kirakoya-Samadoulougou PWLGF, Robert A. Quality of life in people living with HIV: a cross-sectional study in Ouagadougou, Burkina Faso. Springerplus 2014; 3: 372.","DOI":"10.1186\/2193-1801-3-372"},{"key":"1777_CR39","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/09540121.2017.1281879","volume":"29","author":"N Nobre","year":"2017","unstructured":"Nobre N, Pereira M, Roine RP, Sintonen H, Sutinen J. Factors associated with the quality of life of people living with HIV in Finland. AIDS Care. 2017;29:1074\u20138.","journal-title":"AIDS Care"},{"key":"1777_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/2325957415599213","volume":"16","author":"BY Arjun","year":"2015","unstructured":"Arjun BY, Unnikrishnan B, Ramapuram JT, Thapar R, Mithra P, Kumar N, et al. Factors influencing quality of life among people living with HIV in Coastal South India. J Int Assoc Provid AIDS Care. 2015;16:247\u201353.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"1777_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/516369","author":"A Tesfay","year":"2015","unstructured":"Tesfay A, Gebremariam A, Gerbaba M, Abrha H. Gender differences in health related quality of life among people living with HIV on highly active antiretroviral therapy in Mekelle Town, Northern Ethiopia. Biomed Res Int. 2015. https:\/\/doi.org\/10.1155\/2015\/516369.","journal-title":"Biomed Res Int"},{"key":"1777_CR42","first-page":"387","volume":"11","author":"AL Tesemma","year":"2019","unstructured":"Tesemma AL, Abate MG, Abebo ZH, Madebo WE. Determinants of poor quality of life among adults living with HIV and enrolled in highly active antiretroviral therapy at public health facilities of Arba Minch Town Administration in Southern Ethiopia. HIV AIDS. 2019;11:387\u201394.","journal-title":"HIV AIDS"},{"key":"1777_CR43","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.dhjo.2016.06.001","volume":"9","author":"JS de Munter","year":"2016","unstructured":"de Munter JS, Tynelius P, Ahlstr\u00f6m G, Rasmussen F. The bidirectional association between body weight and mobility disability: a population-based cohort. Disabil Health J. 2016;9:632\u20137.","journal-title":"Disabil Health J"},{"key":"1777_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12889-019-6627-2","volume":"19","author":"M Norrb\u00e4ck","year":"2019","unstructured":"Norrb\u00e4ck M, Tynelius P, Ahlstr\u00f6m G, Rasmussen F. The association of mobility disability and obesity with risk of unemployment in two cohorts from Sweden. BMC Public Health. 2019;19:347.","journal-title":"BMC Public Health"},{"key":"1777_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11524-005-9015-4","volume":"83","author":"H-H Thein","year":"2006","unstructured":"Thein H-H, Butler T, Krahn M, Rawlinson W, Levy MH, Kaldor JM, et al. The effect of hepatitis C virus infection on health-related quality of life in prisoners. J Urban Heal. 2006;83:275\u201388.","journal-title":"J Urban Heal"},{"key":"1777_CR46","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1010539511403800","volume":"24","author":"N Toghianifar","year":"2012","unstructured":"Toghianifar N, Najafian J, Pooya A, Rabiei K, Eshrati B, Anaraki J, et al. Association of smoking status with quality of life in a cross-sectional population-based sample of iranian adults: Isfahan healthy heart program. Asia-Pacific J Public Heal. 2012;24:786\u201394.","journal-title":"Asia-Pacific J Public Heal"},{"key":"1777_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0182063","volume":"12","author":"JA Krosnick","year":"2017","unstructured":"Krosnick JA, Malhotra N, Mo CH, Bruera EF, Chang LC, Pasek J, et al. Perceptions of health risks of cigarette smoking: a new measure reveals widespread misunderstanding. PLoS ONE. 2017;12:1\u201323.","journal-title":"PLoS ONE"},{"key":"1777_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.socscimed.2015.06.006","volume":"138","author":"ZD Bailey","year":"2015","unstructured":"Bailey ZD, Slopen N, Albert M, Williams DR. Multidimensional religious involvement and tobacco smoking patterns over 9\u201310 years: a prospective study of middle-aged adults in the United States. Soc Sci Med. 2015;138:128\u201335.","journal-title":"Soc Sci Med"},{"key":"1777_CR49","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/bmj.332.7536.291","volume":"332","author":"N Ghouri","year":"2006","unstructured":"Ghouri N, Atcha M, Sheikh A. Influence of Islam on smoking among Muslims. BMJ Clin Res. 2006;332:291.","journal-title":"BMJ Clin Res"},{"key":"1777_CR50","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1258\/ijsa.2009.008487","volume":"21","author":"RE Campo","year":"2010","unstructured":"Campo RE, Cohen C, Grimm K, Shangguan T, Maa J, Seekins D. Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients. Int J STD AIDS. 2010;21:166\u201371.","journal-title":"Int J STD AIDS"},{"key":"1777_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000004558","volume":"95","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S. Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine. 2016;95:1\u20137.","journal-title":"Medicine"},{"key":"1777_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","volume":"63","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Stepanova M, Afdhal N, Kowdley KV, Zeuzem S, Henry L, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63:337\u201345.","journal-title":"J Hepatol"},{"key":"1777_CR53","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/hepr.12974","volume":"48","author":"T Ichikawa","year":"2018","unstructured":"Ichikawa T, Miyaaki H, Miuma S, Taura N, Motoyoshi Y, Akahoshi H, et al. Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals. Hepatol Res. 2018;48:232\u20139.","journal-title":"Hepatol Res"},{"key":"1777_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.24171\/j.phrp.2018.9.2.03","volume":"9","author":"L Pereira","year":"2018","unstructured":"Pereira L, De MJ, Barreto M, Lima C, Maria M, Pires A, et al. Treatment with sofosbuvir and daclatasvir (with or without ribavirin) improves patient reported outcomes in hepatitis C. Osong Public Heal Res Perspect. 2018;9:50\u20138.","journal-title":"Osong Public Heal Res Perspect"},{"key":"1777_CR55","doi-asserted-by":"publisher","first-page":"e5914","DOI":"10.1097\/MD.0000000000005914","volume":"96","author":"ZM Younossi","year":"2017","unstructured":"Younossi ZM, Stepanova M, Esteban R, Jacobson I, Zeuzem S, Sulkowski M, et al. Superiority of interferon-free regimens for chronic hepatitis C. Medicine (Baltimore). 2017;96:e5914.","journal-title":"Medicine (Baltimore)"},{"key":"1777_CR56","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cgh.2016.10.037","volume":"15","author":"ZM Younossi","year":"2017","unstructured":"Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, et al. Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol. 2017;15:421-30.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1777_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0150655","volume":"11","author":"JS Doyle","year":"2016","unstructured":"Doyle JS, Grebely J, Spelman T, Alavi M, Matthews G, Thompson AJ, et al. Quality of life and social functioning during treatment of recent hepatitis C infection: a multi-centre prospective cohort. PLoS ONE. 2016;11:1\u201316.","journal-title":"PLoS ONE"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-021-01777-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-021-01777-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-021-01777-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:37:51Z","timestamp":1675355871000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-021-01777-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1777"],"URL":"https:\/\/doi.org\/10.1186\/s12955-021-01777-x","relation":{},"ISSN":["1477-7525"],"issn-type":[{"type":"electronic","value":"1477-7525"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics Committee at the Faculty of Medicine Universitas Indonesia approved the study before initiation. Each participant gave their written informed consent after explanation of the study procedure and purpose. Permission was given for the collection of medical data from medical records. Trained researchers were available to assist when needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}